Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × Biguanides × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Insulin Resistance 1 Diabetes Mellitus, Type 2 1

Interventions

Docetaxel 155 Magnetic Resonance Spectroscopy 130 Radiotherapy 127 Prednisone 101 Leuprolide 101 Radiosurgery 94 enzalutamide 93 Androgen Antagonists 84 Abiraterone Acetate 83 Goserelin 74 bicalutamide 70 gallium 68 PSMA-11 61 apalutamide 53 Surveys and Questionnaires 53 Specimen Handling 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 52 Radiation 44 Biopsy 42 Gonadotropin-Releasing Hormone 41 Brachytherapy 41 Standard of Care 38 abiraterone 37 Blood Specimen Collection 35 darolutamide 34 cabazitaxel 34 Exercise 33 Radiotherapy, Intensity-Modulated 32 Carboplatin 32 Triptorelin Pamoate 29 Pluvicto 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02497638 2021-04-19

LIGAND

University Health Network, Toronto

Phase 2 Withdrawn

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡